RU2010114016A - Применение пептида в качестве терапевтического средства - Google Patents
Применение пептида в качестве терапевтического средства Download PDFInfo
- Publication number
- RU2010114016A RU2010114016A RU2010114016/15A RU2010114016A RU2010114016A RU 2010114016 A RU2010114016 A RU 2010114016A RU 2010114016/15 A RU2010114016/15 A RU 2010114016/15A RU 2010114016 A RU2010114016 A RU 2010114016A RU 2010114016 A RU2010114016 A RU 2010114016A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- diseases
- ala
- inflammatory
- fibrosis
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 8
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 claims abstract 7
- 208000019693 Lung disease Diseases 0.000 claims abstract 7
- 230000004761 fibrosis Effects 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 7
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract 6
- 206010040047 Sepsis Diseases 0.000 claims abstract 6
- 201000011510 cancer Diseases 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 208000015181 infectious disease Diseases 0.000 claims abstract 6
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 5
- 208000035473 Communicable disease Diseases 0.000 claims abstract 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 5
- 208000030159 metabolic disease Diseases 0.000 claims abstract 5
- 230000004770 neurodegeneration Effects 0.000 claims abstract 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 5
- 206010040070 Septic Shock Diseases 0.000 claims abstract 4
- 230000002757 inflammatory effect Effects 0.000 claims abstract 4
- 210000004204 blood vessel Anatomy 0.000 claims abstract 3
- 230000001684 chronic effect Effects 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 208000011580 syndromic disease Diseases 0.000 claims abstract 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 2
- 241000894006 Bacteria Species 0.000 claims abstract 2
- 208000009137 Behcet syndrome Diseases 0.000 claims abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 2
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract 2
- 206010014824 Endotoxic shock Diseases 0.000 claims abstract 2
- 241000192125 Firmicutes Species 0.000 claims abstract 2
- 201000005569 Gout Diseases 0.000 claims abstract 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims abstract 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 2
- 208000002260 Keloid Diseases 0.000 claims abstract 2
- 206010023330 Keloid scar Diseases 0.000 claims abstract 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract 2
- 201000010001 Silicosis Diseases 0.000 claims abstract 2
- 201000002661 Spondylitis Diseases 0.000 claims abstract 2
- 206010052779 Transplant rejections Diseases 0.000 claims abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims abstract 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims abstract 2
- 208000006673 asthma Diseases 0.000 claims abstract 2
- 210000004556 brain Anatomy 0.000 claims abstract 2
- 206010006451 bronchitis Diseases 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims abstract 2
- 208000007451 chronic bronchitis Diseases 0.000 claims abstract 2
- 208000016097 disease of metabolism Diseases 0.000 claims abstract 2
- 208000019622 heart disease Diseases 0.000 claims abstract 2
- 210000001117 keloid Anatomy 0.000 claims abstract 2
- 208000032839 leukemia Diseases 0.000 claims abstract 2
- 210000004072 lung Anatomy 0.000 claims abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract 2
- 210000004165 myocardium Anatomy 0.000 claims abstract 2
- 201000008482 osteoarthritis Diseases 0.000 claims abstract 2
- 230000002062 proliferating effect Effects 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 201000000306 sarcoidosis Diseases 0.000 claims abstract 2
- 230000037390 scarring Effects 0.000 claims abstract 2
- 230000036303 septic shock Effects 0.000 claims abstract 2
- 230000035939 shock Effects 0.000 claims abstract 2
- 208000017520 skin disease Diseases 0.000 claims abstract 2
- 208000019553 vascular disease Diseases 0.000 claims abstract 2
- 206010006895 Cachexia Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- -1 lyoprotector Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
Abstract
1. Применение пептида Glu-Ala-Leu-Glu-Leu-Ala-Arg-Gly-Ala-Ile-Phe-Gln-Ala-NH2 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из ревматоидного артрита, остеоартрита, подагрического артрита, спондилита, тироид-ассоциированной офтальмопатии, болезни Бехчета, сепсиса, септического шока, эндотоксического шока, сепсиса грамотрицательными бактериями, сепсиса грамположительными бактериями, синдрома токсического шока, астмы, хронического бронхита, респираторного дистресс-синдрома взрослых, хронического воспалительного заболевания легких, хронического обструктивного заболевания легких, силикоза, саркоидоза легких, реперфузионного повреждения миокарда, реперфузионного повреждения головного мозга, реперфузионного повреждения конечностей, фиброза, кистозного фиброза, келоидного образования, образования рубцов, атеросклероза, реакций отторжения трансплантата, реакции "трансплантат против хозяина", отторжения аллотрансплантата, хронического гломерулонефрита, волчанки, воспалительного заболевания кишечника, болезни Крона, язвенного колита, пролиферативных лимфоцитарных заболеваний, лейкоза, воспалительных дерматозо
Claims (9)
1. Применение пептида Glu-Ala-Leu-Glu-Leu-Ala-Arg-Gly-Ala-Ile-Phe-Gln-Ala-NH2 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из ревматоидного артрита, остеоартрита, подагрического артрита, спондилита, тироид-ассоциированной офтальмопатии, болезни Бехчета, сепсиса, септического шока, эндотоксического шока, сепсиса грамотрицательными бактериями, сепсиса грамположительными бактериями, синдрома токсического шока, астмы, хронического бронхита, респираторного дистресс-синдрома взрослых, хронического воспалительного заболевания легких, хронического обструктивного заболевания легких, силикоза, саркоидоза легких, реперфузионного повреждения миокарда, реперфузионного повреждения головного мозга, реперфузионного повреждения конечностей, фиброза, кистозного фиброза, келоидного образования, образования рубцов, атеросклероза, реакций отторжения трансплантата, реакции "трансплантат против хозяина", отторжения аллотрансплантата, хронического гломерулонефрита, волчанки, воспалительного заболевания кишечника, болезни Крона, язвенного колита, пролиферативных лимфоцитарных заболеваний, лейкоза, воспалительных дерматозов, атопического дерматита, псориаза, крапивницы, кардиомиопатий, застойной сердечной недостаточности, лихорадки, кахексии, вторичной кахексии по отношению к инфекции или злокачественной опухоли, вторичной кахексии по отношению к синдрому приобретенного иммунного дефицита, комплекса, связанного со СПИД, церебральной малярии, остеопороза, заболеваний резорбции кости, инфекционной лихорадки, инфекционных миалгий, несахарного диабета и депрессии.
3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
5. Фармацевтическая композиция, содержащая пептид Glu-Ala-Leu-Glu-Leu-Ala-Arg-Gly-Ala-Ile-Phe-Gln-Ala-NH2, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора.
7. Фармацевтическая композиция по п.6 или 5, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и детям дошкольного возраста.
9. Фармацевтическая композиция по п.5 или 6, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезней обмена веществ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07017756.3 | 2007-09-11 | ||
| EP07017756 | 2007-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010114016A true RU2010114016A (ru) | 2011-10-20 |
Family
ID=40445663
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113996/15A RU2010113996A (ru) | 2007-09-11 | 2008-09-09 | Применение кальцитонина в качестве антиангиогенного средства |
| RU2010114016/15A RU2010114016A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
| RU2010114030/15A RU2010114030A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113996/15A RU2010113996A (ru) | 2007-09-11 | 2008-09-09 | Применение кальцитонина в качестве антиангиогенного средства |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010114030/15A RU2010114030A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20100256043A1 (ru) |
| EP (4) | EP2187948A2 (ru) |
| JP (3) | JP2010539007A (ru) |
| KR (3) | KR20100061484A (ru) |
| AU (3) | AU2008297566A1 (ru) |
| CA (3) | CA2698976A1 (ru) |
| RU (3) | RU2010113996A (ru) |
| WO (10) | WO2009033746A2 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008153788A2 (en) | 2007-05-30 | 2008-12-18 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof |
| US9669092B2 (en) * | 2011-02-02 | 2017-06-06 | Emory University | Antagonism of the VIP signaling pathway |
| US20130123168A1 (en) * | 2011-06-17 | 2013-05-16 | The Regents Of The University Of California | Humanin and humanin-analogues for the management of atherosclerosis |
| JP2013028587A (ja) * | 2011-06-20 | 2013-02-07 | Incorporated Educational Institution Meisei | 抗炎症剤 |
| ES2425448B8 (es) * | 2012-03-12 | 2015-03-17 | Universidade De Santiago De Compostela | Uso de la obestatina para la regeneración muscular |
| US20150038674A1 (en) * | 2013-08-05 | 2015-02-05 | Bayrak Bertan Boran | Use of glp-2 analogues in pulmonary diseases for therapeutic purpose |
| US9458217B2 (en) | 2013-12-05 | 2016-10-04 | Emory University | Methods of managing graft versus host disease |
| WO2016035820A1 (ja) * | 2014-09-02 | 2016-03-10 | 学校法人東京理科大学 | 中枢作用性ペプチド誘導体及び医薬組成物 |
| US11274158B2 (en) * | 2018-01-30 | 2022-03-15 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators |
| CN109867860A (zh) * | 2019-02-12 | 2019-06-11 | 青岛科技大学 | 一种具有良好光热稳定性的阻燃聚丙烯材料及其制备方法 |
| CN111700063B (zh) * | 2020-06-29 | 2021-03-30 | 广州瑞铂茵健康科技有限公司 | 一种脐带标本的保存方法 |
| US11367521B1 (en) * | 2020-12-29 | 2022-06-21 | Kpn Innovations, Llc. | System and method for generating a mesodermal outline nourishment program |
| KR102573754B1 (ko) * | 2021-02-25 | 2023-09-01 | 주식회사 차메디텍 | 신규의 펩타이드 및 이를 포함하는 피부장벽 강화 또는 피부가려움증 억제를 위한 화장료 조성물 |
| CN117164668B (zh) * | 2023-08-01 | 2024-05-10 | 青岛双元泰和药业有限公司 | 多肽化合物、其组合物及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4537878A (en) * | 1981-10-05 | 1985-08-27 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to stimulate the immune system |
| EP0313158A3 (en) * | 1987-10-23 | 1990-08-22 | Merck & Co. Inc. | Gastrin releasing peptide antagonist |
| JP3160013B2 (ja) * | 1991-06-21 | 2001-04-23 | 三菱化学株式会社 | 新規ペプチド |
| DE69128283T2 (de) | 1991-08-12 | 1998-03-19 | Nestle Sa | Nahrungsmittelzusammensetzung |
| JPH06172386A (ja) * | 1992-12-10 | 1994-06-21 | Mitsubishi Kasei Corp | 新規ペプチド |
| JPH07157437A (ja) * | 1993-12-03 | 1995-06-20 | Mitsubishi Chem Corp | シナプス長期増強剤 |
| JPH07206700A (ja) * | 1994-01-26 | 1995-08-08 | Mitsubishi Chem Corp | 神経細胞死抑制剤 |
| CZ262698A3 (cs) | 1996-02-19 | 1999-03-17 | Nycomed Imaging A/S | Kontrastní prostředek pro zobrazování ultrazvukem a způsob jeho výroby |
| TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
| ATE193636T1 (de) | 1996-09-24 | 2000-06-15 | Nestle Sa | Milchaustauschprodukt und verfahren zu dessen herstellung |
| FR2775902B1 (fr) * | 1998-03-13 | 2001-05-11 | Assist Publ Hopitaux De Paris | Utilisation d'analogues du vip dans la prevention et le traitement des lesions cerebrales du nouveau-ne humain |
| AU771034B2 (en) | 1998-11-24 | 2004-03-11 | Societe Des Produits Nestle S.A. | Method for preparing a protein composition and an infant formula containing same |
| EP1173195B1 (en) * | 1999-04-21 | 2007-10-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS |
| JP4628627B2 (ja) * | 1999-09-17 | 2011-02-09 | 学校法人慶應義塾 | 疾患抑制遺伝子のスクリーニング方法 |
| AU2001256998A1 (en) * | 2000-04-11 | 2001-11-07 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
| US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| PT1326630E (pt) * | 2000-09-18 | 2008-09-02 | Sanos Bioscience As | Utilização de péptidos glp-2 |
| EP1360202B1 (en) * | 2001-02-16 | 2008-05-21 | ConjuChem Biotechnologies Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| WO2002092018A2 (en) * | 2001-05-16 | 2002-11-21 | Plotnikoff Nicholas P | Methods for inducing sustained immune response |
| EP1314357B1 (en) | 2001-11-23 | 2007-05-23 | Société des Produits Nestlé S.A. | Process for the preparation of milk powders and concentrated milk products |
| AU2003242340A1 (en) * | 2002-06-14 | 2003-12-31 | Takeda Pharmaceutical Company Limited | Novel screening method |
| CA2506850C (en) * | 2002-11-20 | 2014-05-13 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| WO2006019365A1 (en) * | 2003-05-09 | 2006-02-23 | Curagen Corporation | Novel humanin-like polypeptides and polynucleotides and their methods of use |
| WO2005082404A2 (en) * | 2004-02-27 | 2005-09-09 | Novo Nordisk A/S | Glp-2 derivatives modified by lipophilic substituents |
| WO2005120545A1 (en) * | 2004-06-11 | 2005-12-22 | Vectus Biosystems Limited | Compositions and methods for treatment of cardiovascular disease |
| AU2005294125A1 (en) * | 2004-10-08 | 2006-04-20 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| WO2006088765A1 (en) * | 2005-02-14 | 2006-08-24 | Wisconsin Alumni Research Foundation | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
| MX2007010930A (es) * | 2005-03-07 | 2008-03-14 | Mondobiotech Licensing Out Ag | Formulacion de aviptadil. |
| EP1861416A1 (en) * | 2005-03-09 | 2007-12-05 | The Board of Trustees of Leland Stanford Junior University | Obestatin and its uses |
| EP1885391A1 (en) * | 2005-05-19 | 2008-02-13 | Novo Nordisk A/S | Use of glp-2 for the treatment of ischemia-reperfusion injury |
| US20080039393A1 (en) * | 2005-11-09 | 2008-02-14 | Desmond Mascarenhas | Metal-binding therapeutic peptides |
| JP2009530407A (ja) * | 2006-03-23 | 2009-08-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト |
| DK2059254T3 (en) * | 2006-08-31 | 2015-07-13 | Spectrum Pharmaceuticals Inc | Sensitization of tumor cells to radiation therapy by administration of endothelin agonists |
| WO2008153788A2 (en) * | 2007-05-30 | 2008-12-18 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof |
-
2008
- 2008-09-09 WO PCT/EP2008/007794 patent/WO2009033746A2/en not_active Ceased
- 2008-09-09 US US12/677,753 patent/US20100256043A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007810 patent/WO2009040050A2/en not_active Ceased
- 2008-09-09 RU RU2010113996/15A patent/RU2010113996A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007984 patent/WO2009033791A2/en not_active Ceased
- 2008-09-09 KR KR1020107005642A patent/KR20100061484A/ko not_active Withdrawn
- 2008-09-09 EP EP08802129A patent/EP2187948A2/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007577 patent/WO2009033714A2/en not_active Ceased
- 2008-09-09 WO PCT/EP2008/007993 patent/WO2009033794A2/en not_active Ceased
- 2008-09-09 JP JP2010523380A patent/JP2010539007A/ja active Pending
- 2008-09-09 RU RU2010114016/15A patent/RU2010114016A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007539 patent/WO2009039991A2/en not_active Ceased
- 2008-09-09 AU AU2008297566A patent/AU2008297566A1/en not_active Abandoned
- 2008-09-09 JP JP2010523425A patent/JP2010539052A/ja active Pending
- 2008-09-09 JP JP2010523414A patent/JP2010539041A/ja active Pending
- 2008-09-09 KR KR1020107005615A patent/KR20100056513A/ko not_active Withdrawn
- 2008-09-09 EP EP08802479A patent/EP2187929A2/en not_active Withdrawn
- 2008-09-09 CA CA2698976A patent/CA2698976A1/en not_active Abandoned
- 2008-09-09 CA CA2699008A patent/CA2699008A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007982 patent/WO2009033790A2/en not_active Ceased
- 2008-09-09 US US12/677,266 patent/US20100197587A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007710 patent/WO2009040017A2/en not_active Ceased
- 2008-09-09 CA CA2699052A patent/CA2699052A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005657A patent/KR20100057060A/ko not_active Withdrawn
- 2008-09-09 US US12/677,551 patent/US20100204116A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007618 patent/WO2009043447A2/en not_active Ceased
- 2008-09-09 EP EP08802333A patent/EP2187947A2/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007620 patent/WO2009043449A2/en not_active Ceased
- 2008-09-09 AU AU2008303812A patent/AU2008303812A1/en not_active Abandoned
- 2008-09-09 RU RU2010114030/15A patent/RU2010114030A/ru not_active Application Discontinuation
- 2008-09-09 US US12/677,803 patent/US20100197599A1/en not_active Abandoned
- 2008-09-09 EP EP08802242A patent/EP2195012A2/en not_active Withdrawn
- 2008-09-09 AU AU2008297888A patent/AU2008297888A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010113965A (ru) | Гамма-1-msh отдельно или в сочетании с пентагастрином в качестве терапевтического средства | |
| RU2010114016A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114020A (ru) | Trap-14 в качестве терапевтического средства | |
| RU2010114046A (ru) | Применение пептидов maippkknqdk (коровий казеин каппа 106-116) и/или ygfqna (серорфин) в качестве терапевтических средств | |
| RU2010113966A (ru) | Применение меланотропинстимулирующего фактора в качестве терапевтического средства | |
| RU2010114054A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
| RU2010113985A (ru) | Применение уродилатина в качестве терапевтического средства | |
| RU2010114007A (ru) | Применение комбинации пептидов cart в качестве терапевтического средства | |
| RU2010113992A (ru) | Применение урокортина и кортиколиберина в качестве терапевтических средств | |
| RU2010114023A (ru) | ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА | |
| RU2010113979A (ru) | Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv | |
| JP2011523412A5 (ru) | ||
| JP2018515531A5 (ru) | ||
| WO2009046847A3 (en) | Use of peptide ll-37 as a therapeutic agent | |
| RU2010114048A (ru) | Применение пептида дефензина в качестве терапевтического средства | |
| RU2010113990A (ru) | Применение пептида ламинина в качестве терапевтического средства | |
| WO2009040029A3 (en) | Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis | |
| RU2010114052A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114039A (ru) | Применение октреотида в качестве терапевтического средства | |
| RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства | |
| RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства | |
| RU2010114060A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2021134333A (ru) | Новые трициклические антагонисты 5-ht2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |